FDA Adverse Event Injury Summary report: N

1-DAY ACUVUE TRUEYE (NARAFILCON B)

MDR report key: 2960539 · Received February 12, 2013

Report

Report Number
1033553-2013-00010
Event Type
Injury
Date Received
February 12, 2013
Date of Event
February 14, 2011
Report Date
February 12, 2013
Manufacturer
VISTAKON
Product Code
LPL
PMA / PMN Number
K100349
Adverse Event
Yes
Report Source
Manufacturer report
Reporter Location
GA, US
Reporter Occupation
NOT APPLICABLE

Narratives

Additional Manufacturer Narrative · 1

METHOD: DEVICE NOT RETURNED. NO EVALUATION WILL BE PERFORMED. CONCLUSIONS: NO CONCLUSION CAN BE DRAWN.

Description of Event or Problem · 1

WHILE REVIEWING INFORMATION ON THE CLINICALTRIALS.GOV WEBSITE, AN ASSOCIATE IN OUR FIRM FOUND A SUBJECT TAKING PART IN A CLINICAL TRIAL FOR CIBA VISION WAS WEARING A 1-DAY ACUVUE TRUEYE CONTACT LENS AND DEVELOPED A STERILE INFILTRATE WITH A SECONDARY IRITIS. (B)(4). ON (B)(6) 2011, THE SUBJECT AWOKE WITH PAIN AND PHOTOPHOBIA. THE PT WAS EXAMINED BY THE INVESTIGATOR THAT DAY AND WAS FOUND TO HAVE A STERILE INFILTRATE WITH SECONDARY IRITIS. THE INFILTRATE WAS 1 X 2 MM AND THE IRITIS WAS QUANTIFIED AS 1 TO 3 CELLS WITH DROPS ON DAY 1 AND TOBRADEX DROPS Q1H ON DAY ONE AND THEN QID. THE SUBJECT WAS SEEN FOR FOLLOW-UP ON (B)(6) AND THE LAST VISIT WAS ON (B)(6) 2011; THE STERILE INFILTRATE AND IRITIS HAD RESOLVED AND THE PT RESUMED THE STUDY. THE LENSES WERE NOT AVAILABLE FOR EVALUATION. THE LOT NUMBER WAS PROVIDED AND A LOT HISTORY REVIEW WAS PERFORMED AND REVEALED THE FOLLOWING: THE BATCH RECORD DID NOT SHOW ANY ABNORMALITIES IN MONOMER AND SOLUTION TESTING. ALL PARAMETERS TESTED WERE WITHIN SPECIFICATIONS. ALL STERILIZATION REQUIREMENTS WERE SUCCESSFULLY COMPLETED. LOT 1338250105 WAS PRODUCED UNDER NORMAL CONDITIONS. MDR REPORTABLE EVENT TRENDS ARE REVIEWED QUARTERLY IN FRANCHISE MANAGEMENT REVIEW MEETINGS.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
60887 1-DAY ACUVUE TRUEYE (NARAFILCON B) SOFT CONTACT LENS LPL VISTAKON NA 1338250105

Patients

Seq Age Sex Outcome Treatment
1 UNK Other